Skip to main content
SpringerLink
Log in

Borderline Resectable Adrenal Cortical Carcinoma: A Potential Role for Preoperative Chemotherapy

  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Background

Adrenal cortical carcinoma (ACC) may have tumor or patient characteristics at presentation that argue against immediate surgery because of an unacceptable risk of morbidity/mortality, incomplete resection, or recurrence. This clinical stage can be characterized as borderline resectable ACC (BRACC). At present, systemic therapies in ACC can reduce tumor burden in some patients, creating an opportunity in BRACC for a strategy of preoperative chemotherapy (ctx) followed by surgery.

Materials and Methods

A single-institution retrospective review was conducted of all patients considered for surgery for primary ACC. Patients with BRACC treated with preoperative ctx were categorized as follows: group A, imaging suggesting a need for multiorgan/vascular resection; group B, imaging suggesting potentially resectable oligometastases; and group C, patients having marginal performance status/comorbidities precluding immediate surgery. Both the disease-free survival (DFS) and the overall survival (OS) were compared in BRACC patients treated with preoperative ctx+surgery and those who had upfront surgery.

Results

Fifty-three patients with primary ACC were considered for surgery (median follow-up: 49.9 months). Thirty-eight patients (71.7 %) had initial surgery and 15 of them (28.3 %) were considered BRACC and received preoperative therapy. Of these 15 patients, 12 (80 %) received combination therapy with mitotane and etoposide/cisplatin-based ctx, 2 (13 %) received mitotane alone, and 1 (7 %) received ctx alone. Six patients were defined as group A, 5 as group B, and 4 as group C. Thirteen (87 %) BRACC patients underwent surgical resection. BRACC patients were younger but had more advanced disease than the patients having initial surgery (stage IV in 40 vs 2.6 % [p < 0.01]). By Response Evaluation Criteria In Solid Tumors criteria, 5 patients (38.5 %) had a partial response, 7 (53.8 %) had stable disease, and 1 (7.7 %) had disease that progressed. Postoperative mitotane use was similar between groups (p = .15). Median DFS for resected BRACC patients was 28.0 months [95 % confidence interval (CI), 2.9–not attained] vs 13 months (95 % CI, 5.8–46.9) (p = 0.40) for initial surgery patients. Five-year OS rates were also similar: 65 % for resected BRACC vs 50 % for initial surgery (p = 0.72).

Conclusions

The favorable outcome of patients with BRACC, despite more advanced stage of disease compared to those treated with surgery first, together with uncommon disease progression, suggests a benefit of neoadjuvant treatment sequencing in patients with BRACC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Fassnacht M, Johanssen S, Quinkler M et al (2009) Limited prognostic value of the 2004 international union against cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 115:243–250

    Article  PubMed  Google Scholar 

  2. Maluf DF, de Oliveira BH, Lalli E (2011) Therapy of adrenocortical cancer: present and future. Am J Cancer Res 1:222–232

    PubMed Central  PubMed  Google Scholar 

  3. Kerkhofs TM, Verhoeven RH, Van der Zwan JM et al (2013) Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer 49:2579–2586

    Article  PubMed  Google Scholar 

  4. Stigliano A, Cerquetti L, Sampaoli C et al (2012) Current and emerging therapeutic options in adrenocortical cancer treatment. J Oncol 2012:408131

    Article  PubMed Central  PubMed  Google Scholar 

  5. Grubbs EG, Callender GG, Xing Y et al (2010) Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol 17:263–270

    Article  PubMed  Google Scholar 

  6. Terzolo M, Angeli A, Fassnacht M et al (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 356:2372–2380

    Article  CAS  PubMed  Google Scholar 

  7. Fassnacht M, Terzolo M, Allolio B et al (2012) Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366:2189–2197

    Article  CAS  PubMed  Google Scholar 

  8. Katz MH, Pisters PW, Evans DB et al (2008) Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206:833–846 discussion 846–848

    Article  PubMed  Google Scholar 

  9. Tempero MA, Arnoletti JP, Behrman S et al (2010) Pancreatic adenocarcinoma. J Natl Compr Cancer Netw 8:972–1017

    CAS  Google Scholar 

  10. Lughezzani G, Sun M, Perrotte P et al (2010) The European network for the study of adrenal tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. Eur J Cancer 46:713–719

    Article  PubMed  Google Scholar 

  11. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Compr Cancer Netw 92:205–216

    Article  CAS  Google Scholar 

  12. Bourdeau I, Mackenzie-Feder J, Lacroix A (2013) Recent advances in adrenocortical carcinoma in adults. Curr Opin Endocrinol Diabetes Obes 20:192–197

    Article  CAS  PubMed  Google Scholar 

  13. Zini L, Porpiglia F, Fassnacht M (2011) Contemporary management of adrenocortical carcinoma. Eur Urol 60:1055–1065

    Article  PubMed  Google Scholar 

  14. Gonzalez RJ, Tamm EP, Ng C et al (2007) Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery 142:867–875 discussion 875

    Article  PubMed  Google Scholar 

  15. Abrams RA, Lowy AM, O’Reilly EM et al (2009) Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 16:1751–1756

    Article  PubMed  Google Scholar 

  16. Evans DB, Farnell MB, Lillemoe KD et al (2009) Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 16:1736–1744

    Article  PubMed  Google Scholar 

  17. Vauthey JN, Dixon E (2009) AHPBA/SSO/SSAT consensus conference on resectable and borderline resectable pancreatic cancer: rationale and overview of the conference. Ann Surg Oncol 16:1725–1726

    Article  PubMed  Google Scholar 

  18. Berruti A, Fassnacht M, Baudin E et al (2010) Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol 28:e401–e402 author reply e3

    Article  PubMed  Google Scholar 

  19. Datrice NM, Langan RC, Ripley RT et al (2012) Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol 105:709–713

    Article  PubMed  Google Scholar 

  20. Gaujoux S, Al-Ahmadie H, Allen PJ et al (2012) Resection of adrenocortical carcinoma liver metastasis: is it justified? Ann Surg Oncol 19:2643–2651

    Article  PubMed  Google Scholar 

  21. Kemp CD, Ripley RT, Mathur A et al (2011) Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience. Ann Thorac Surg 92:1195–1200

    Article  PubMed  Google Scholar 

  22. Hermsen IG, Kerkhofs TM, den Butter G et al (2012) Surgery in adrenocortical carcinoma: importance of national cooperation and centralized surgery. Surgery 152:50–56

    Article  PubMed  Google Scholar 

  23. Miller BS, Gauger PG, Hammer GD et al (2012) Resection of adrenocortical carcinoma is less complete and local recurrence occurs sooner and more often after laparoscopic adrenalectomy than after open adrenalectomy. Surgery 152:1150–1157

    Article  PubMed  Google Scholar 

Download references

Disclosures

The authors have no disclosures.

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1484, Houston, TX, 77030, USA

    Brian K. Bednarski, Nicholas Vauthey, Matthew H. Katz, Nancy D. Perrier, Jeffrey E. Lee & Elizabeth G. Grubbs

  2. Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

    Mouhammed Amir Habra

  3. Department of Medical Oncology, Methodist Cancer Center, Houston, TX, 77030, USA

    Alexandria Phan

  4. Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

    Denai R. Milton

  5. Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

    Christopher Wood

  6. Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, 53226, USA

    Douglas B. Evans

  7. Department of Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

    Chaan S. Ng

Authors
  1. Brian K. Bednarski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mouhammed Amir Habra
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexandria Phan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Denai R. Milton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christopher Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nicholas Vauthey
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Douglas B. Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Matthew H. Katz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chaan S. Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Nancy D. Perrier
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jeffrey E. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Elizabeth G. Grubbs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth G. Grubbs.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bednarski, B.K., Habra, M.A., Phan, A. et al. Borderline Resectable Adrenal Cortical Carcinoma: A Potential Role for Preoperative Chemotherapy. World J Surg 38, 1318–1327 (2014). https://doi.org/10.1007/s00268-014-2484-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-014-2484-4

Keywords

Search

Navigation